A carregar...
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
BACKGROUND: The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or in...
Na minha lista:
Publicado no: | BMC Neurol |
---|---|
Main Authors: | , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4253981/ https://ncbi.nlm.nih.gov/pubmed/25424122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-014-0220-1 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|